Lexaria Bioscience Corp. (LEXX)
LEXX Stock Price Chart
Explore Lexaria Bioscience Corp. interactive price chart. Choose custom timeframes to analyze LEXX price movements and trends.
LEXX Company Profile
Discover essential business fundamentals and corporate details for Lexaria Bioscience Corp. (LEXX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
12 Jan 2021
Employees
7.00
CEO
Richard C. Christopher
Description
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
LEXX Financial Timeline
Browse a chronological timeline of Lexaria Bioscience Corp. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Apr 2026
Upcoming earnings on 25 Nov 2025
EPS estimate is -$0.17.
Earnings released on 14 Jul 2025
EPS came in at -$0.21 falling short of the estimated -$0.15 by -40.00%, while revenue for the quarter reached $174.00K , beating expectations by +27.01%.
Earnings released on 14 Apr 2025
EPS came in at -$0.15 surpassing the estimated -$0.16 by +6.25%, while revenue for the quarter reached $174.00K , beating expectations by +90.52%.
Earnings released on 10 Jan 2025
EPS came in at -$0.16 falling short of the estimated -$0.12 by -33.33%, while revenue for the quarter reached $183.92K , beating expectations by +83.92%.
Earnings released on 26 Nov 2024
EPS came in at -$0.15 falling short of the estimated -$0.11 by -36.36%, while revenue for the quarter reached $84.00K , missing expectations by -16.00%.
Earnings released on 12 Jul 2024
EPS came in at -$0.13 falling short of the estimated -$0.09 by -44.44%, while revenue for the quarter reached $84.00K , missing expectations by -44.00%.
Earnings released on 9 Apr 2024
EPS came in at -$0.06 surpassing the estimated -$0.10 by +40.00%, while revenue for the quarter reached $145.00K .
Earnings released on 12 Jan 2024
EPS came in at -$0.13 falling short of the estimated -$0.11 by -18.18%, while revenue for the quarter reached $151.28K .
Earnings released on 21 Nov 2023
EPS came in at -$0.12 surpassing the estimated -$0.17 by +29.41%, while revenue for the quarter reached -$3.43K .
Earnings released on 14 Jul 2023
EPS came in at -$0.37 falling short of the estimated -$0.25 by -48.00%, while revenue for the quarter reached $93.15K , missing expectations by -45.21%.
Earnings released on 14 Apr 2023
EPS came in at -$0.22 , while revenue for the quarter reached $20.03K , missing expectations by -89.46%.
Earnings released on 17 Jan 2023
EPS came in at -$0.30 , while revenue for the quarter reached $101.48K .
Earnings released on 25 Nov 2022
EPS came in at -$0.24 falling short of the estimated -$0.21 by -14.29%, while revenue for the quarter reached $111.15K , missing expectations by -43.00%.
Earnings released on 14 Jul 2022
EPS came in at -$0.41 falling short of the estimated -$0.28 by -46.43%, while revenue for the quarter reached $99.72K , missing expectations by -16.90%.
Earnings released on 11 Apr 2022
EPS came in at -$0.25 falling short of the estimated -$0.21 by -19.05%, while revenue for the quarter reached $30.65K , missing expectations by -79.57%.
Earnings released on 14 Jan 2022
EPS came in at -$0.35 , while revenue for the quarter reached $13.88K .
Earnings released on 29 Nov 2021
EPS came in at -$0.22 surpassing the estimated -$0.23 by +4.35%, while revenue for the quarter reached $31.02K , beating expectations by +0.07%.
Earnings released on 15 Jul 2021
EPS came in at -$0.40 , while revenue for the quarter reached $204.06K .
Earnings released on 14 Apr 2021
EPS came in at -$0.28 , while revenue for the quarter reached $192.01K .
Earnings released on 14 Jan 2021
EPS came in at -$0.24 , while revenue for the quarter reached $295.66K .
Stock split effective on 12 Jan 2021
Shares were split 1 : 30 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 15 Oct 2020
EPS came in at -$0.26 , while revenue for the quarter reached $133.74K .
LEXX Stock Performance
Access detailed LEXX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.